[1] Kou XG, Liang DL, Zhang QQ, et al. Analysis of prognostic factors in 68 patients with cancer of unknown primary site[J]. Zhonghua Zhong Liu Za Zhi, 2011, 33(10): 783-786.
[2] Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP)[J]. Crit Rev Oncol Hematol, 2009, 69(3): 271-278.
[3] Varadhachary GR, Abhruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer[J]. Cancer, 2004, 100(9): 1776-1785.
[4] Molina R, Bosch X, Auge JM, et al. Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site[J]. Tumor Biol, 2012, 33(2): 463-474.
[5] Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths[J]. CA Cancer J Clin, 2011, 61(4): 212-236.
[6] Kwee TC, Basus, Cheng G, et al. FDG PET/CT in carcinoma of unknown primary [J]. Eur J Nucl Med Mol Imaging, 2010, 37(3): 635-644.
[7] Hemminki K, Ji J, Sundquist J, et al. Familial risks in cancer of unknown primary: tracking the primary sites[J]. J Clin Oncol, 2011, 29(4): 435-440.
[8] Pavilidis N, Pentheroudakis G. Cancer of unknown primary site[J]. Lancet, 2012, 379(9824): 1428-1435.
[9] Kwee TC, Kwee RM. Combined FDGPET/CT for the detection of unknown primary tumors: systematic review and metaanalysis[J]. Eur Radiol, 2009, 19(3): 731-744.
[10] Hainswroth JD, Rubin MS, Spiqel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct sitespecific therapy in patients with carcinoma of unknown primary site: a prospective trial of the sarah cannon research institute[J]. J Clin Oncol, 2013, 31(2): 217-223.
[11] Wang Y, Li YM, Yin YF. Clinical value of 18FFDG PET/CT in detection of original disease of patients with malignant ascites[J]. Chin J Med Imaging Technol, 2012, 28(12): 2193-2196.
[12]Roh JL, Kim JS, Lee JH, et al. Utility of combined 18FFDG PET/CT in patients with cervical metastases from unknown primary tumors[J]. Oral Oncol, 2009, 45(3): 218-224.
[13]Chang JM, Lee HJ, Goo JM, et al. False positive and false negative FDGPET scans in various thoracic diseases[J]. Korean J Radiol, 2006, 7(1): 57-69.
[14]MercierVogel L, Couson F, Kohlik M, et al. Impact of breast MRI and PETCT in breast cancer staging[J]. Rev Med Suisse, 2010, 6(250): 1076-1078.
[15]Dong MJ, Zhao K, Lin XT, et al. Role of FDG PET versus FDGPET/CT in detection of unknown primary tumor: a metaanalysis of the literature[J]. Nucl Med Commun, 2008, 29(9): 791-802.
[16]Greco FA. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management[J]. Curr Treat Options Oncol, 2013, 14(4): 634-642.
[17]Keller F, Psychogios G, Linke R, et al. Carcinoma of unknown primary in the head and neck: comparison between PET and PET/CT[J]. Head Neck, 2011, 33(11): 1569-1575.
[18]Monzon FA, LyonsWeiler M, Buturovic LJ, et al. Multicenter validation of a 1,550gene expression profile for identification of tumor tissue of origin[J]. J Clin Oncol, 2009, 27(15): 2503-2508.
[19]Rosenwald S, Gilad S, Benjamin S, et al. Validation of a microRNAbased qRTPCR test for accurate identification of tumor tissue origin[J]. Mod Pathol, 2010, 23(6): 814-823.
[20]Greco FA, Spigel DR, Yardley DA, et al. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction[J]. Oncologist, 2010, 15(5): 500-506.
[21]Greco FA, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognosis factors[J]. Semin Oncol, 2009, 36(1): 65-74.
[22]Culine S. Prognostic factors in unknown primary cancer[J]. Semin Oncol, 2009, 36(1): 60-64.
[23]Hainsworth JD, Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors[J]. Semin Oncol, 2009, 36(1): 44-51.
[24]Escudier B, Bellmunt J, Négrier S, et al. Phase Ⅲ trial of bevacizumal plus interferon alfa2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival[J]. J Clin Oncol, 2010, 28(13): 2144-2150. |